XML 45 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders Deficit (Tables)
9 Months Ended
Sep. 30, 2017
Equity [Abstract]  
Summary of Stock Option Plans Activity

A summary of the Plan’s stock option activity is as follows:

 

 

 

Number of

Shares

 

 

Weighted-

Average

Exercise Price

Per Share

 

 

Weighted-

Average

Remaining

Contractual

Life (Years)

 

 

Aggregate

Intrinsic Value

 

Balance at December 31, 2016

 

 

1,161,705

 

 

$

3.35

 

 

7.7

 

 

$

36,887

 

Granted

 

 

474,000

 

 

 

2.10

 

 

 

 

 

 

 

 

 

Exercised

 

 

(41,815

)

 

2.68

 

 

 

 

 

 

$

152,130

 

Forfeited

 

 

(54,758

)

 

 

2.78

 

 

 

 

 

 

 

 

 

Expired/Cancelled

 

 

(6,153

)

 

 

10.08

 

 

 

 

 

 

 

 

 

Balance at September 30, 2017

 

 

1,532,979

 

 

$

2.98

 

 

 

7.8

 

 

$

-

 

Exercisable at September 30, 2017

 

 

803,458

 

 

$

3.32

 

 

 

6.6

 

 

$

-

 

 

As of September 30, 2017, there was total unrecognized compensation expense of $1,266,892 related to unvested stock options, which the Company expects to recognize over a weighted-average period of approximately 1.74 years.

Summary of RSU Plans Activity

A summary of the Plan’s RSU activity is as follows:

 

 

 

Restricted

Stock Units

(RSU)

 

 

Weighted-

Average

Grant Date

Fair Value

Per Share

 

Balance at December 31, 2016

 

 

355,499

 

 

$

2.41

 

Granted

 

 

10,000

 

 

 

1.75

 

Vested

 

 

(328,000

)

 

 

2.45

 

Forfeited

 

 

(2,500

)

 

 

2.46

 

Balance at September 30, 2017

 

 

34,999

 

 

$

1.91

 

 

Summary of Stock-Based Compensation

Stock-based compensation expense recorded in the condensed statements of operations for the three and nine months ended September 30, 2017 and 2016 was as follows:

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2017

 

 

2016

 

 

2017

 

 

2016

 

Selling, general and administrative

 

$

251,924

 

 

$

166,167

 

 

$

826,098

 

 

$

399,760

 

Research and development

 

 

79,619

 

 

 

49,891

 

 

 

261,083

 

 

 

117,681

 

Cost of revenue

 

 

25,862

 

 

 

13,860

 

 

 

84,807

 

 

 

34,613

 

 

 

$

357,405

 

 

$

229,918

 

 

$

1,171,988

 

 

$

552,054